Jump to content
RemedySpot.com

Re: Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer

Rate this topic


Guest guest

Recommended Posts

Very Welcome News!

(Chuck) Maack

Prostate Cancer Advocate

Bio: http://www.ustoowichita.org/leaders.cfm?content=bio & id=1

Email: maack1@...

>

>

http://money.cnn.com/news/newsfeeds/articles/prnewswire/CLTU0662310200

7-1.htm

> Dendreon Completes Target Enrollment of 500 Patients in Phase 3

IMPACT Study

> of Provenge® For Advanced Prostate Cancer

> --FDA Has Agreed That Positive Survival Data from IMPACT Study

Would Support

> Licensure of PROVENGE---Interim Survival Results Expected in Second

Half of

> 2008--

>

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...